or Try an Advanced Search...

    Technical Analysis for HEPA - Hepion Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.29 -2.27% -0.03
    HEPA closed down 2.27 percent on Thursday, April 25, 2024, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 13
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical HEPA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish -2.27%
    Older End-of-Day Signals for HEPA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 12 hours ago
    60 Minute Opening Range Breakout about 15 hours ago
    Up 1% about 15 hours ago
    Rose Above Lower Bollinger Band about 16 hours ago
    Down 3% about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    HEPA Chart by TradingView
    Basic chart:

    Profile

    Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Phosphates Hepatitis B Lipid Liver Disease Hepatotoxins Treatment Of Hepatitis Cyclophilin Drug Therapy Gilead Sciences Chronic Liver Diseases Treatment Of Hepatitis B Chronic Liver Disease Tenofovir Disoproxil

    Is HEPA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 22 S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
    Apr 19 Hepion ends Phase 2 study for NASH drug due to cash restraints
    Apr 19 Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
    Mar 6 Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
    Feb 16 Hepion announces exercise of warrants for about $2M gross proceeds
    Feb 16 Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
    Jan 3 Hepion Pharmaceuticals to Present at NASH-TAG 2024
    Dec 7 Hepion Pharma announces restructuring plan, sees $400–800 thousand charge for 4Q
    Dec 7 Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
    Nov 28 Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
    See more HEPA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.66
    52 Week Low 1.22
    Average Volume 73,181
    200-Day Moving Average 4.14
    50-Day Moving Average 2.29
    20-Day Moving Average 2.13
    10-Day Moving Average 1.82
    Average True Range 0.26
    RSI (14) 26.47
    ADX 23.0
    +DI 11.84
    -DI 32.40
    Chandelier Exit (Long, 3 ATRs) 2.13
    Chandelier Exit (Short, 3 ATRs) 1.99
    Upper Bollinger Bands 2.96
    Lower Bollinger Band 1.30
    Percent B (%b) 0.0
    BandWidth 77.96
    MACD Line -0.24
    MACD Signal Line -0.13
    MACD Histogram -0.1135
    Fundamentals Value
    Market Cap 5.6 Million
    Num Shares 4.34 Million
    EPS -12.42
    Price-to-Earnings (P/E) Ratio -0.10
    Price-to-Sales 0.00
    Price-to-Book 0.46
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.41
    Resistance 3 (R3) 1.42 1.38 1.39
    Resistance 2 (R2) 1.38 1.35 1.38 1.38
    Resistance 1 (R1) 1.34 1.33 1.32 1.33 1.38
    Pivot Point 1.30 1.30 1.29 1.30 1.30
    Support 1 (S1) 1.26 1.27 1.24 1.25 1.20
    Support 2 (S2) 1.22 1.25 1.22 1.20
    Support 3 (S3) 1.18 1.22 1.19
    Support 4 (S4) 1.17